Ftse Mib
38.456,17
0,09%
DAX
22.425,93
0,73%
S&P 500
6.026,52
0,22%
NASDAQ
19.480,27
-0,22%
Bitcoin
94.899,29
-1,43%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Cyclo Therapeutics Inc (CYTH) Cyclo Therapeutics Inc (CYTH) Notizie

CYTH

Cyclo Therapeutics (CYTH)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CYTH
DataOraFonteTitoloSimboloCompagnia
07/02/202514:05Business WireCyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)NASDAQ:CYTHCyclo Therapeutics Inc
14/01/202514:05Business WireCyclo Therapeutics to Present at the 21st Annual WORLDSymposium™ 2025NASDAQ:CYTHCyclo Therapeutics Inc
11/12/202413:00GlobeNewswire Inc.Rafael Holdings Reports First Quarter Fiscal 2025 Financial ResultsNASDAQ:CYTHCyclo Therapeutics Inc
14/11/202414:05Business WireCyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:CYTHCyclo Therapeutics Inc
07/11/202401:14GlobeNewswire Inc.Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial ResultsNASDAQ:CYTHCyclo Therapeutics Inc
21/10/202414:00GlobeNewswire Inc.Pacira BioSciences Appoints Shawn Cross as Chief Financial OfficerNASDAQ:CYTHCyclo Therapeutics Inc
05/09/202415:05Business WireCyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)NASDAQ:CYTHCyclo Therapeutics Inc
26/08/202415:37PR Newswire (US)Kuehn Law Encourages CYTH, ARCH, CEIX, and VGR Investors to Contact Law FirmNASDAQ:CYTHCyclo Therapeutics Inc
22/08/202415:37Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:CYTHCyclo Therapeutics Inc
22/08/202415:36Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CYTHCyclo Therapeutics Inc
22/08/202412:50GlobeNewswire Inc.Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger AgreementNASDAQ:CYTHCyclo Therapeutics Inc
22/08/202412:50Business WireRafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger AgreementNASDAQ:CYTHCyclo Therapeutics Inc
20/08/202419:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTHCyclo Therapeutics Inc
15/08/202415:00Business WireCyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:CYTHCyclo Therapeutics Inc
14/08/202423:28Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CYTHCyclo Therapeutics Inc
29/07/202415:05Business WireCyclo Therapeutics Announces Notice of Decision to Grant European Patent Application for Treatment of Alzheimer’s Disease from European Patent OfficeNASDAQ:CYTHCyclo Therapeutics Inc
25/06/202415:25Business WireCyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024NASDAQ:CYTHCyclo Therapeutics Inc
14/06/202422:01GlobeNewswire Inc.Rafael Holdings Reports Third Quarter Fiscal 2024 Financial ResultsNASDAQ:CYTHCyclo Therapeutics Inc
30/05/202415:00Business WireCyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1NASDAQ:CYTHCyclo Therapeutics Inc
16/05/202414:05Business WireCyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:CYTHCyclo Therapeutics Inc
18/03/202414:05Business WireCyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:CYTHCyclo Therapeutics Inc
14/03/202414:34Business WireCyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s DiseaseNASDAQ:CYTHCyclo Therapeutics Inc
13/03/202422:04GlobeNewswire Inc.Rafael Holdings Reports Second Quarter Fiscal 2024 Financial ResultsNASDAQ:CYTHCyclo Therapeutics Inc
04/03/202422:33Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:CYTHCyclo Therapeutics Inc
14/02/202420:44Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CYTHCyclo Therapeutics Inc
29/01/202415:15Business WireCyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark OfficeNASDAQ:CYTHCyclo Therapeutics Inc
29/12/202303:48Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CYTHCyclo Therapeutics Inc
27/12/202322:15Business WireCyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.NASDAQ:CYTHCyclo Therapeutics Inc
18/12/202315:15Business WireCyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1NASDAQ:CYTHCyclo Therapeutics Inc
14/12/202322:01GlobeNewswire Inc.Rafael Holdings Reports First Quarter Fiscal 2024 Financial ResultsNASDAQ:CYTHCyclo Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CYTH

La tua Cronologia

BIT
SPM
Saipem
BIT
UCG
Unicredit
BIT
STLAM
Stellantis NV
BIT
ISP
Intesa Sanpaolo
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
LDO
Leonardo
BIT
ENEL
Enel
BIT
BPE
Bper Banca
BIT
PRY
Prysmian
BIT
STMMI
ST Microelectronics
BIT
BAMI
Banco BPM
BIT
ENI
Eni
BIT
TIT
Telecom Italia
BIT
RACE
Ferrari NV
BIT
G
Generali
BIT
CPR
Davide Campari
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci